---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-013323"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-10-24T23:59:59+00:00"
generated_at: "2026-06-09T15:11:14.195404+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI's Multikine shows 28% absolute 5-year survival benefit in head & neck cancer target population at ESMO

## Summary
- Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.
- 5-year survival 73% with Multikine vs 45% control (p=0.0015); hazard ratio 0.35, 65% risk reduction.
- Pre-surgery disease downstaging observed in 35% of Multikine patients; linked to improved survival.
- Pre-application regulatory filings submitted in UK and Europe; plans to file in US and Canada for immediate approval without confirmatory study.

## SEC filing metadata
- accession: 0001654954-23-013323
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/0001654954-23-013323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-013323
- JSON: https://secwatch.observer/filing/0001654954-23-013323.json
- Plain text: https://secwatch.observer/filing/0001654954-23-013323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.